IDEXX Laboratories (NASDAQ:IDXX) Issues FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 14.290-14.800 for the period, compared to the consensus earnings per share estimate of 14.450. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $4.7 billion.

Analysts Set New Price Targets

Several research firms recently issued reports on IDXX. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Morgan Stanley increased their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Barclays assumed coverage on IDEXX Laboratories in a research note on Monday, December 8th. They issued an “overweight” rating and a $850.00 price objective for the company. Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $760.50.

IDEXX Laboratories Trading Down 4.6%

Shares of NASDAQ:IDXX opened at $639.60 on Tuesday. The company has a market capitalization of $51.07 billion, a PE ratio of 50.72, a PEG ratio of 3.58 and a beta of 1.67. IDEXX Laboratories has a 12-month low of $356.14 and a 12-month high of $769.98. The business has a 50 day moving average of $703.10 and a two-hundred day moving average of $662.65. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the firm earned $2.53 EPS. The business’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts forecast that IDEXX Laboratories will post 11.93 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.98% of the company’s stock.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q4 results beat expectations — EPS $3.08 vs. $2.93 estimate and revenue $1.091B vs. $1.07B estimate; revenue rose ~14% YoY and margins expanded, underscoring solid near-term profitability. IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Companion Animal Group (CAG) remains the primary growth engine — reported CAG growth of ~15% (13% organic); company cites innovation driving 8%–10% CAG diagnostics growth going forward. Idexx targets $4.632B–$4.720B revenue for 2026 as innovation drives 8%–10% CAG diagnostics growth
• Neutral Sentiment: FY‑2026 guidance: revenue $4.632B–$4.720B and EPS $14.29–$14.80 (company noted resilient vet demand and higher tests-per-visit). The range is roughly in line with, but not meaningfully above, consensus — a mixed data point for future growth modeling. IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics
• Neutral Sentiment: Full earnings call/transcript and slide deck are available for detail (useful for modeling margin trajectory, regional dynamics and product-cycle assumptions). IDEXX Laboratories, Inc. (IDXX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market reaction was negative — shares dipped despite the beat as investors parsed guidance that some viewed as conservative relative to recent momentum; pre-market selling cited in coverage. IDEXX Laboratories tops revenue forecasts, shares edge lower on outlook
• Negative Sentiment: Valuation and near‑term expectations could constrain upside — the stock trades at a rich multiple, so any guidance shortfall or slowing clinic-visit trends may pressure the stock. IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise

Institutional Trading of IDEXX Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virtus Advisers LLC purchased a new position in IDEXX Laboratories in the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $36,000. WealthCollab LLC purchased a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $30,000. Johnson Financial Group Inc. boosted its stake in shares of IDEXX Laboratories by 1,475.0% in the third quarter. Johnson Financial Group Inc. now owns 63 shares of the company’s stock worth $40,000 after acquiring an additional 59 shares during the last quarter. Finally, Pin Oak Investment Advisors Inc. acquired a new stake in shares of IDEXX Laboratories in the third quarter worth approximately $60,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.